Legend Biotech (LEGN) Cash from Financing Activities (2019 - 2026)
Legend Biotech's (LEGN) quarterly Cash from Financing Activities came in at -$1.2 million in Q1 2026, down 300.0% YoY from $600000.0 in Q1 2025, and down 100.0% on a QoQ basis from -$600000.0 in Q4 2025.
Legend Biotech (LEGN) Cash from Financing Activities (2019 - 2026) Analysis & Trends
Legend Biotech (LEGN) has 8 years of Cash from Financing Activities data on file, last reported at -$1.2 million in Q1 2026.
- Quarterly Cash from Financing Activities fell 300.0% year-over-year to -$1.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$2.1 million (down 137.33% YoY) and the FY2025 annual result came in at -$300000.0, down 105.26% from the prior year.
- Cash from Financing Activities slipped to -$1.2 million in Q1 2026, from -$600000.0 in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $790.0 million in Q2 2023 to a low of -$1.2 million in Q1 2026.
- A 5-year average of $69.0 million and a median of $670000.0 in 2025 frame the typical range for Cash from Financing Activities.
- The widest YoY moves for Cash from Financing Activities: up 78200.1% in 2023, down 1876.0% in 2023.
- Tracing LEGN's Cash from Financing Activities over 5 years: stood at -$783000.0 in 2022, then surged by 218.14% to $925000.0 in 2023, then plunged by 132.43% to -$300000.0 in 2024, then sank by 100.0% to -$600000.0 in 2025, then sank by 100.0% to -$1.2 million in 2026.
- The last three Cash from Financing Activities figures came in at -$1.2 million (Q1 2026), -$600000.0 (Q4 2025), and $670000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.42 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -6.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -207,909.22 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -273.15 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 36.24 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 27.18 Mn |
| 10 | Legend Biotech | 3.95 Bn | 3.27 Bn | 251.50 Mn | 167.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 167.70 Mn |
| Jun 30, 2026 | 167.70 Mn |
| Mar 31, 2026 | -1.20 Mn |
| Mar 31, 2026 | -1.20 Mn |
| Dec 31, 2025 | -600,000.00 |
| Dec 31, 2025 | -600,000.00 |
| Sep 30, 2025 | 670,000.00 |
| Sep 30, 2025 | 670,000.00 |
| Jun 30, 2025 | -923,000.00 |
| Jun 30, 2025 | -923,000.00 |
| Mar 31, 2025 | 600,000.00 |
| Mar 31, 2025 | 600,000.00 |
| Dec 31, 2024 | -300,000.00 |
| Dec 31, 2024 | -300,000.00 |
| Sep 30, 2024 | 4.25 Mn |
| Sep 30, 2024 | 4.25 Mn |
| Jun 30, 2024 | 955,000.00 |
| Jun 30, 2024 | 955,000.00 |
| Mar 31, 2024 | 831,000.00 |
| Mar 31, 2024 | 831,000.00 |